Sen. Bernie Sanders' April 21 report argued Trump's policies have not broadly lowered prices; it found companies that struck deals launched new drugs priced on average $353,000 per year, raised existing prices, and together earned $177 billion in 2025 (a 66% rise), while CEOs' pay climbed to $346 million combined (up 24%). Sanders won rare Republican support for a bill to tie U.S. prices to Europe and Canada, but it failed to reach the 60-vote threshold. Kennedy acknowledged many drugs remain outside agreements and Americans still generally pay more.
The exchange follows other public moments in which Trump touted TrumpRx and RFK Jr. — who recently praised Trump as unusually "sane" — defended the administration's record, creating a combustible mix of politics and arithmetic on the Hill.